
Opinion|Videos|July 10, 2024
EHA 2024 Insights: Impact of the IMROZ Study on Newly Diagnosed Multiple Myeloma
Joseph Mikhael, MD, discusses the latest trends and innovations regarding multiple myeloma management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please discuss the data presented at the European Hematology Association 2024 (EHA 2024) Hybrid Congress on the IMROZ study of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) vs VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).
- Please provide your key takeaways from this study. How do the results of this study impact the treatment of patients with transplant-ineligible NDMM?
Advertisement
Related to this article

Real-world acne treatment adherence spans 6% to 84%, with cost, adverse effects, and slow results driving nonadherence.

A value-based care pilot within Kentucky’s Medicaid program reduced total costs for adults with substance use disorder while improving utilization of evidence-based treatments.

A scalable, symptom-focused patient education model paired with coordinated podiatric care offers managed care organizations a low-barrier strategy to reduce diabetic foot ulcers and costly amputations.

Pimicotinib, a once-daily oral CSF-1R inhibitor, is now FDA approved for adults with TGCT for whom surgery may worsen function or cause severe morbidity.

Pooled real-world data show an 88% response rate with brexu-cel in relapsed mantle cell lymphoma (MCL), but cost and QOL data are scarce.

Employer diabetes guide; Camden psychedelic therapy input; CRC after EMR; rural HFrEF care; JAMA obesity report.

This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.
Advertisement
Advertisement
Trending on AJMC
1
Health Equity & Access Weekly Roundup: November 20, 2026
2
FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor
3
Defining High-Efficacy MS Therapy: Access, Formularies, and Patient Choice
4
Four Ways to Boost Awareness, Access for COVID-19 PEP
5

